SGO 2024 Insights: "RUBY Part 1 & Part 2 Trial - Dostarlimab + Chemo for Primary Advanced/Recurrent Endometrial Cancer & PARPi Maintenance in Patients Receiving Dostarlimab + Chemo"

0 views
April 9, 2024
Comments 0
Login to view comments. Click here to Login